October 2022

home / publications / directions-in-pharmacy / october-2022-ptoe
Experts Review Current Treatment Space, Future Directions in Basal Cell Carcinoma

Experts Review Current Treatment Space, Future Directions in Basal Cell Carcinoma

Aislinn Antrim, Assistant Managing Editor
October 19th 2022
Article

Pharmacist involvement in identifying causes and treatment approaches is essential, as BCC can be a result of prior radiation therapy.

Tebentafusp-tebn Use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal Melanoma

Tebentafusp-tebn Use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal Melanoma

Samantha Brongiel, PharmD, BCOP
October 18th 2022
Article

The agent is representative of a new class of drug, ImmTAC.

Use of Lutetium Lu-177 Vipivotide Tetraxetan to Treat Metastatic Castration-Resistant Prostate Cancer

Use of Lutetium Lu-177 Vipivotide Tetraxetan to Treat Metastatic Castration-Resistant Prostate Cancer

Stephanie Trexler, PharmD, BCOP
October 17th 2022
Article

The FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.

Assessing Quadruplet vs Triplet Regimens in Up-front Multiple Myeloma Treatment

Assessing Quadruplet vs Triplet Regimens in Up-front Multiple Myeloma Treatment

Sarah Schmidt, PharmD, BCOP
October 14th 2022
Article

Research indicates quadruplet regimens may be a viable option for this disease.

Navigating Drug Resistance in Chronic Myelocytic Leukemia

Navigating Drug Resistance in Chronic Myelocytic Leukemia

Grace Baek, PharmD, BCOP
October 13th 2022
Article

Opportunities for further optimization of CML management remain.

Controlled Substances Prescribing Goes Electronic

Controlled Substances Prescribing Goes Electronic

Alberto Coustasse-Hencke, DrPH, MD, MBA, MPH;Ken Maxik, MBA, BSPharm;Craig Kimble, PharmD, MBA, MS, BCACP
October 12th 2022
Article

Eliminating paper prescriptions allows for greater legibility, security, trackability for pharmacists and providers.

Oral Oncolytics Expand Armamentarium in HR+/HER– Early-Stage Breast Cancer in Adjuvant Setting

Oral Oncolytics Expand Armamentarium in HR+/HER– Early-Stage Breast Cancer in Adjuvant Setting

Michelle Nguyen, PharmD Candidate;Grace Baek, PharmD, BCOP;Arianne Duong, PharmD, BCOP;Dane Fritzsche, PharmD, BCOP
October 11th 2022
Article

New agents can offer a more tailored approach to therapy selection.

Oncology Pharmacists Can Drive New Strategies to Resolve Disparities in Breast Cancer Care, Patient Outcomes

Oncology Pharmacists Can Drive New Strategies to Resolve Disparities in Breast Cancer Care, Patient Outcomes

Lisa E. Davis, PharmD, FCCP, BCPS, BCOP
October 3rd 2022
Article

Oncology pharmacists participate significantly in conversations, research, and publications of that research.

Racial Disparities in Breast Cancer Mortality Persist, Oncology Pharmacy Can Make a Difference

Racial Disparities in Breast Cancer Mortality Persist, Oncology Pharmacy Can Make a Difference

Mike Hennessy Jr, President and CEO
October 1st 2022
Article

October is Breast Cancer Awareness Month.

Prescribing Controlled Substances Goes Electronic

Prescribing Controlled Substances Goes Electronic

Alberto Coustasse-Hencke, DrPH, MD, MBA, MPH;Ken Maxik, MBA, BSPharm;Craig Kimble, PharmD, MBA, MS, BCACP
September 21st 2022
Article

Eliminating paper prescriptions allows for greater legibility, security, trackability for pharmacists, providers.